2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2616

Ischemia-Modified Albumin : A Novel Marker of Vascular Involvement in Behcet’s Disease ?
Abstract Number: 2037

Isolated Anti-Ro52 Antibody – Significance and Clinical Association
Abstract Number: 14

Isotype Dependent Performance Of Beta₂glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization
Abstract Number: 1362

Isymind Significantly Reduces MTX-Induced Nausea In a Pilot Trial
Abstract Number: 285

Juvenile Idiopathic Arthritis Patients Demonstrate Alterations In HDL Functionality Without Accelerated Subclinical Atherosclerosis
Abstract Number: 2178

Juvenile Onset Systemic Sclerosis: Clinical and Serological Features, and Mortality In Comparison With Adult Onset Disease
Abstract Number: 2001

Kaiser Permanent Pyramid In Patients With Gout: The Most Severe Gout Is Associated To The Most Complex Patients
Abstract Number: L19

Kellgren-Lawrence Grade (KL) 0 Vs. KL 1 Knees Differ in Their MRI Predictors of Subsequent Radiographic Osteoarthritis
Abstract Number: 2876

Key Rheumatoid Arthritis-Associated Pathogenic Pathways Revealed By Integrative Analysis Of RA Omics Datasets
Abstract Number: 2902

Key Roles For Interferon and Macrophage Activation In Progressive Lung Fibrosis Associated With Systemic Sclerosis
Abstract Number: 2004

Kidney Disease Is An Independent Risk Factor For Incident Gout
Abstract Number: 92

Kidney Function and Alcohol Intake and The Risk Of Incident Gout In a Population-Based Cohort Of Adults: Atherosclerosis Risk In Communities Study
Abstract Number: L16

Kidney Resident B Cells and Plasmacytoid Dendritic Cells in Urine of Systemic Lupus Erythematosus patients
Abstract Number: 2019

Kikuchi-Fujimoto disease : Features and Outcome Of 91 Patients In France
Abstract Number: 2055

Killer T Cell Inhibition By CD226 Blockade For Treatment Of Inflammatory Myopathy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].